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ORIGINAL ARTICLEVisual and Semiquantitative Accuracy in Clinical Baseline
123I-Ioflupane SPECT/CT ImagingRudolf A. Werner, MD,*†‡Charles Marcus, MD,*§ Sara Sheikhbahaei, MD,* Lilja B. Solnes, MD, MPH,*
Jeffrey P. Leal, BA,* Yong Du, PhD,* Steven P. Rowe, MD, PhD,* Takahiro Higuchi, MD, PhD,†‡||
Andreas K. Buck, MD,†‡ Constantin Lapa, MD,† and Mehrbod S. Javadi, MD*Purpose:We aimed to (a) elucidate the concordance of visual assessment of an
initial 123I-ioflupane scan by a human interpreter with comparison to results using
a fully automatic semiquantitativemethod and (b) to assess the accuracy compared
to follow-up (f/u) diagnosis established by movement disorder specialists.
Methods: An initial 123I-ioflupane scan was performed in 382 patients with
clinically uncertain Parkinsonian syndrome. An experienced reader performed a
visual evaluation of all scans independently. The findings of the visual readwere
compared with semiquantitative evaluation. In addition, available f/u clinical di-
agnosis (serving as a reference standard) was compared with results of the hu-
man read and the software.
Results: When comparing the semiquantitative method with the visual as-
sessment, discordance could be found in 25 (6.5%) of 382 of the cases for
the experienced reader (ĸ = 0.868). The human observer indicated region of
interest misalignment as the main reason for discordance. With neurology
f/u serving as reference, the results of the reader revealed a slightly higher ac-
curacy rate (87.7%, ĸ = 0.75) compared to semiquantification (86.2%,
ĸ = 0.719, P < 0.001, respectively). No significant difference in the diagnostic
performance of the visual read versus software-based assessment was found.
Conclusions: In comparison with a fully automatic semiquantitative
method in 123I-ioflupane interpretation, human assessment obtained an al-
most perfect agreement rate. However, compared to clinical established di-
agnosis serving as a reference, visual read seemed to be slightly more
accurate as a solely software-based quantitative assessment.
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Clinical Nuclear Medicine • Volume 44, Number 1, January 2019123I -N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane [123I-FP-CIT, 123I-ioflupane (GE Healthcare,
Waukesha, WI)] has been utilized in numerous studies and clinical
trials to differentiate between patients with nigrostriatal degenera-
tion versus patients without neurodegeneration.1–3 Most commonly,
the result of an 123I-ioflupane scan is based on visual assessment and
binary reporting, but several concerns have been raised with regard
to solely using visual analysis to interpret those scans, e.g. its intrin-
sically subjective nature4–6 or the impact of ageing on dopamine
transporter loss.7–9 Therefore, novel semiquantification approaches
including a region of interest (ROI) setting on relevant anatomical
structures (i.e., striatum, consisting of caudate nucleus and putamen)
are increasingly embedded in clinical routine.5,10,11 However, these
semiquantitative methods also present several challenges, including
ROI misalignment in borderline cases, qualitative or artificial
asymmetry, or arbitrary setting of predefined ROI.10,12 In this
monocentric setting, we aimed to elucidate the agreement rate
between visual interpretation of an initial 123I-ioflupane scan by
an experienced reader with a fully automatic semiquantitative
method and to assess the reasons that might hamper its diagnostic
accuracy. Moreover, we aimed to assess the accuracy of those
methods with comparison to criteria-based neurology follow-up
(f/u) established by Movement Disorder Specialists.MATERIALS AND METHODS
In total, 382 patients with clinically uncertain parkinsonian
syndrome who underwent a baseline 123I-ioflupane single photon
emission computed tomography/computed tomography (SPECT/CT)
were included. All patients had been clinically referred from our insti-
tutionalMovementDisorders Center to assist in diagnosis andwere an-
alyzed as part of an institutional review board–approved protocol
(Johns Hopkins University, Baltimore, MD, USA).
Imaging Procedure and Fully Automatic
Semiquantitative Analysis
Integrated SPECT/CTusing a Symbia T2 (Siemens, Erlangen,
Germany) equipped with a low-energy, high-resolution collimator
was performed in all patients. The obtained data were analyzed using
a Xeleris Workstation (DaTQUANT 4.0, GE Healthcare, Waukesha,
WI). Regions of interest were automatically defined over the caudate
nucleus, putamen, and striatum bilaterally, as well as over the occip-
ital cortex serving as a nonspecific reference region. Themean counts
measured by separate ROI over the specific-striatal regions were then
divided by the mean counts measured in the occipital region.13 The
derived ratios define the specific uptake in each of those investigated
basal ganglion regions. As each center needs to establish its own cut-
off for interpretation,10 the cutoff used within our institution is a value
of 1.6 within any of the investigated striatal-specific regions.www.nuclearmed.com 1
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Imaging Interpretation
An experienced reader, blinded to the clinical status and neu-
rological diagnosis, performed a visual evaluation of all scans inde-
pendently (binary reporting). If the findings were discordant with
the semiquantitative analysis, the predefined ROIs were displayed
and the human observer indicated a reason for the inconsistent findings.
These were (1) ROI misalignment, (2) qualitative asymmetry be-
tween different specific-striatal regions, or (3) increased background
activity by visual assessment of the reference region.
Accuracy Assessment—Comparison With
Neurology Follow-up
The clinical diagnosis was assessed based on clinical
criteria by Movement Disorder Specialists.14 To assess the accu-
racy of the human assessment and the semiquantification, the avail-
able criteria-based follow-up (f/u) clinical diagnosis served as a
criterion standard.
Statistical Analysis
The degree of agreement between visual, semiquantitative
assessment, and neurology f/u as a reference standard were
assessed using the Cohen κ coefficient (κ).15 A κ value of less
than 0.2, 0.2–0.4, 0.4–0.6, 0.6–0.8, and 0.8–1.0 indicate slight,
fair, moderate, substantial and almost perfect agreement, respec-
tively.15 McNemar test was performed to compare the perfor-
mance of visual and semiquantitative assessment. The relation
between the semiquantitative uptake in putamen and visual
assessment of 123I-ioflupane scan is shown in a scatter plot. Sta-
tistical analysis was performed using IBM SPSS Statistics (ver-
sion 22; Chicago, IL). The statistical significance level was set
at P < 0.05.FIGURE 1. Baseline 123I-ioflupane scans in 382 patients with
clinically uncertain parkinsonian syndrome with each dot
representing an individual subject. Semiquantitative ratios for
the right and left putamen as well as the results for an
experienced reader are given. Upper panel indicates the
concordant (i.e., similar results to software) and lower panel
displays the discordant cases (i.e., inconsistent results
compared to software) for the human observer (κ = 0.868,
P < 0.001). Dashed lines indicate the institutional reference
cutoff ratio for the software,10 solid lines indicate the mean.RESULTS
One hundred sixty-eight (44%) of 382 patients were female;
the median age of the entire cohort was 66 years (range,
17–93 years). The fully automatic semiquantitative evaluation
method revealed the following ratios [median (range)]: striatum
right, 1.74 (0.2–4.38); striatum left, 1.79 (0.21–4.32); putamen right,
1.47 (0.1–4.34); putamen left, 1.47 (0.13–4.16); caudate right, 2.17
(0.38–4.46); caudate left, 2.24 (0.28–4.87). The software rated 163
(42.7%) of 382 normal [visual assessment, 178/382 (46.6%)]. When
comparing the software-derived findings with the visual read, a discor-
dance could be found in 25 of 382 (6.5%, ĸ = 0.868, P < 0.001, i.e.,
almost-perfect reproducibility) cases. The reasons for the discordances
were as follows: ROI misalignment (16/25, 64%), qualitative asym-
metry (5/25, 20%), and increased background activity (4/25, 16%).
Figure 1 displays the semiquantitative values for the putamenversus
the visual read.
Of the 382 investigated cases, our institutional Movement
Disorders Center established a final clinical diagnosis in 138
(36.1%) of 382 after a median f/u of 29 ± 16.1 months, and a neuro-
degenerative disease was ruled out in 63 (45.7%) of 138. The experi-
enced reader rated 58 (42.0%) of 138 of the scans normal
[semiquantification, 52/138 (37.7%)]. With neurology f/u serving
as criterion standard, the discordance rate of the experienced reader
was 17 of 138 (12.3%; ĸ = 0.75, P < 0.001). In 11 (64.7%) of 17
cases, the diagnosis by the experienced reader was false positive.
For the semiquantification, a discordance rate of 19 (13.8%) of
138 was observed (ĸ = 0.719, P < 0.001) with false-positive find-
ings in 15 (78.9%) of 19. There was no significant difference in
the sensitivity or specificity of visual assessment versus software-2 www.nuclearmed.combased analysis. Table 1 displays the diagnostic performance of
both methods.DISCUSSION
In this largest single-center study published to date, the con-
cordance of 123I-ioflupane scan interpretation assessed by an expe-
rienced reader in comparison to a fully automatic semiquantitative
evaluation method revealed an almost-perfect reproducibility© 2018 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Accuracy of Visual Read and Fully Automatic
Semiquantitative Method Compared to Clinically Established
Diagnosis Serving as Reference Standard (n = 138)
Visual Read Semiquantitative Method
Sensitivity, % 92 94.7
Specificity, % 82.5 76.2
Accuracy, % 87.7 86.2
True positive False positive 69 11 71 15
False negative True negative 6 52 4 48
There was no significant difference in the diagnostic performance of the visual
read (performed by an experienced reader) and the semiquantitative method.
Clinical Nuclear Medicine • Volume 44, Number 1, January 2019 Accuracy of Visual 123I-Ioflupane Assessment(ĸ = 0.868). In addition, the agreement with available neurology f/u
can also be described as substantial for both human read and
semiquantification (ĸ ≤ 0.75).15
In previous interagreement studies, ĸ in the range of 0.87 to
0.97 for experienced readers had been obtained.16–18 However, pa-
tients were enrolled from multiple sites (between 10 and 40 different
centers16,17) and one might assume that the SPECT cameras utilized,
their settings, as well as other procedures might not be standardized
among different institutions. In the present study, neither the standard
procedures nor the SPECT camera used changed throughout the as-
sessment. Thus, the herein presented high software-reader agreement
rates in a single-center setting on a larger scale may further under-
score the considerable reliability of 123I-ioflupane imaging. More-
over, the human observer also indicated that ROI misalignment was
the main reason for discordance compared to semiquantification.
Disease progression in Parkinson disease is first reflected by a de-
crease in putaminal uptake and followed subsequently by a reduction
in the caudate.19,20 Consequently, the well-known comma shape of
the striatal-specific regions on a 123I-ioflupane scan might be altered
and a predefined ROI might miss putaminal loss of dopamine trans-
porter binding at an early stage of disease.12 As displayed in Figure 1,
discordant putamen ratio scores tended to be low for the normal vi-
sual assessment and as a possible explanation, those cases may be
formally beyond the institutional cutoff, but appear to be normal in
a visual human read. In addition, putaminal binding ratios tended to
be higher for the abnormal visual assessments. One might hypothesize
that the value in the caudate can have potential impact on the uptake ratio
of theROI defining the adjacent putamen:Although a dopaminergic def-
icit in the putamen can be obviously present in a visual assessment, its
semiquantitative value may be still considerably high but primarily
reflecting the performance of the caudate (“spillover”). Hence, novel ap-
proaches considering potential dysmorphism of the comma shape with
regard to progressive disease, or improvements in ROI alignment to
striatal-specific regions might be intensively sought.12
Although not statistically significant, the visual assessment
seems to be more accurate when compared to the semiquantitative
method, as the human evaluation matched slightly better with available
neurology f/u (accuracy of the experienced observer, 87.7% versus
software, 86.2%; Table 1). Human observers gather information from
the entire scan, which allows for an evaluation of the pattern of uptake
instead of an analysis exclusively obtained by a predefined ROI.21 As
demonstrated in the present study, a reader is able to identify even sub-
tle differences of dopamine transporter binding, e.g., qualitative
asymmetry between different anatomic regions. Obviously, cur-
rent software-based methodologies in place cannot overcome
these hurdles and human observers still seem to be more sensi-
tive to slight correlative variations in uptake patterns.21
The present investigation suffers from several limitations. A
larger prospective study would confirm our preliminary findings.© 2018 Wolters Kluwer Health, Inc. All rights reserved.Clinical follow-up could not be acquired in all investigated cases; how-
ever, this reflects clinical reality, as we relied exclusively on clinical
consensus of experts at our institutional Movement Disorders Center.
CONCLUSION
In the present largest single-center assessment, visual read of
123I-ioflupane scan interpretation was compared to a semiquantita-
tive method. With neurology f/u serving as reference standard, the
visual observer’s interpretation seemed to be more accurate to a
solely software-based quantitative assessment.
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